A comparative study of two doses 15mg versus 30 mg of ketorolac for pain relief in cesarean delivery

Randomized controlled trial to compare 15 mg with 30 mg of intraoperative ketorolac as add on therapy in Cesarean delivery - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/01/061383

Enrollment

240

Registered

2024-01-11

Start date

Unknown

Completion date

Unknown

Last updated

2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O82- Encounter for cesarean delivery without indication

Interventions

Intervention1: Ketorolac: Dose : 15 mg Route: intravenous Frequency: Single Control Intervention1: Ketorolac: Dose: 30 mg Route: intravenous Frequency : Single

Eligibility

Inclusion criteria

Inclusion criteria: Term gestation, Age 18-40 years, ASA physical status I-II, Cesarean delivery, Primary or repeat cesarean section, Pfannenstiel incision Spinal anesthesia.

Exclusion criteria

Exclusion criteria: Bleeding disorder, History of allergy to study drug History of gastrointestinal ulcer Conversion to general anesthesia Obesity (BMI > 35kg/m2) Preeclampsia Renal insufficiency Liver disorder History of bronchial asthma Surgical complications

Design outcomes

Primary

Measure	Time frame
VAS ( Visual Analogue score )Timepoint: baseline 4 hour 12 hour 24 hour	—

Secondary

Measure	Time frame
Time to first dose of rescue analgesiaTimepoint: Hours;Tramadol requirementTimepoint: milligrams	—

Countries

India

Contacts

Public ContactDr Bharti

Dr B R Ambedkar State InstituteOf Medical Sciences Mohali

dr.bhartisidhu@gmail.com9463334042

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026